Postneoadjuvant therapy: a new approach to the treatment of HER2-positive breast cancer (KATHERINE study results)
Up until recently, neoadjuvant and adjuvant treatment regimens for breast cancer (BC) were considered equivalent in their effect on long-term treatment outcomes. Despite the fact that additional information on the prognosis of patients (achievement or failure to achieve complete drug pathomorphosis)...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2019-12-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/5135 |
| _version_ | 1797841626185334784 |
|---|---|
| author | L. G. Zhukova S. A. Smolin |
| author_facet | L. G. Zhukova S. A. Smolin |
| author_sort | L. G. Zhukova |
| collection | DOAJ |
| description | Up until recently, neoadjuvant and adjuvant treatment regimens for breast cancer (BC) were considered equivalent in their effect on long-term treatment outcomes. Despite the fact that additional information on the prognosis of patients (achievement or failure to achieve complete drug pathomorphosis) was obtained during neoadjuvant therapy, we could not change this prognosis, since there was no evidence that any variant of adjuvant therapy could improve survival of patients, who did not achieve complete morphological tumour regression. In December 2018, investigators presented the results of the first planned interim analysis of invasive disease-free survival (iDFS) of patients with early HER2-positive breast cancer, who had residual tumour after neoadjuvant anti-HER2-containing therapy, depending on the adjuvant treatment option: either trastuzumab emtansine (n = 743) or trastuzumab (n = 743). The expected 3-year iDFS in patients, who received trastuzumab emtansine as adjuvant therapy, was 88.3%, while that in the standard trastuzumab group accounted for only 77% (RR = 0.50; 95% CI 0.39–0, 64; h <0.001). The results of the KATHERINE study, which showed an improvement in the survival rates of patients with HER2-positive breast cancer, who did not achieve complete therapeutic pathomorphism (pCR) against the background of neoadjuvant anti-HER2 therapy with the use of trastuzumab emtansine in the adjuvant mode, are not just an important milestone in the treatment of HER2-positive breast cancer. These results reverse the attitude towards neoadjuvant therapy, as we were able, for the first time, to improve the treatment outcome due to the change of the therapy based on therapeutic pathomorphosis data. Thus, this approach leads to the fact that neoadjuvant therapy becomes a more effective technique, at least in HER2-positive breast cancer. |
| first_indexed | 2024-04-09T16:34:21Z |
| format | Article |
| id | doaj.art-54034115ae4b40c38b9bf6c6f070817f |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:34:21Z |
| publishDate | 2019-12-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-54034115ae4b40c38b9bf6c6f070817f2023-04-23T06:56:57ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902019-12-01019445010.21518/2079-701X-2019-19-44-494651Postneoadjuvant therapy: a new approach to the treatment of HER2-positive breast cancer (KATHERINE study results)L. G. Zhukova0S. A. Smolin1State Budgetary Health Institution of the city of Moscow «Loginov Moscow Clinical Research Center» of Moscow Health DepartmentState Budgetary Health Institution of the city of Moscow «Loginov Moscow Clinical Research Center» of Moscow Health DepartmentUp until recently, neoadjuvant and adjuvant treatment regimens for breast cancer (BC) were considered equivalent in their effect on long-term treatment outcomes. Despite the fact that additional information on the prognosis of patients (achievement or failure to achieve complete drug pathomorphosis) was obtained during neoadjuvant therapy, we could not change this prognosis, since there was no evidence that any variant of adjuvant therapy could improve survival of patients, who did not achieve complete morphological tumour regression. In December 2018, investigators presented the results of the first planned interim analysis of invasive disease-free survival (iDFS) of patients with early HER2-positive breast cancer, who had residual tumour after neoadjuvant anti-HER2-containing therapy, depending on the adjuvant treatment option: either trastuzumab emtansine (n = 743) or trastuzumab (n = 743). The expected 3-year iDFS in patients, who received trastuzumab emtansine as adjuvant therapy, was 88.3%, while that in the standard trastuzumab group accounted for only 77% (RR = 0.50; 95% CI 0.39–0, 64; h <0.001). The results of the KATHERINE study, which showed an improvement in the survival rates of patients with HER2-positive breast cancer, who did not achieve complete therapeutic pathomorphism (pCR) against the background of neoadjuvant anti-HER2 therapy with the use of trastuzumab emtansine in the adjuvant mode, are not just an important milestone in the treatment of HER2-positive breast cancer. These results reverse the attitude towards neoadjuvant therapy, as we were able, for the first time, to improve the treatment outcome due to the change of the therapy based on therapeutic pathomorphosis data. Thus, this approach leads to the fact that neoadjuvant therapy becomes a more effective technique, at least in HER2-positive breast cancer.https://www.med-sovet.pro/jour/article/view/5135breast cancerher2-positive breast canceradjuvant therapytrastuzumab emtansinet-dm1katherineidfsresidual tumor |
| spellingShingle | L. G. Zhukova S. A. Smolin Postneoadjuvant therapy: a new approach to the treatment of HER2-positive breast cancer (KATHERINE study results) Медицинский совет breast cancer her2-positive breast cancer adjuvant therapy trastuzumab emtansine t-dm1 katherine idfs residual tumor |
| title | Postneoadjuvant therapy: a new approach to the treatment of HER2-positive breast cancer (KATHERINE study results) |
| title_full | Postneoadjuvant therapy: a new approach to the treatment of HER2-positive breast cancer (KATHERINE study results) |
| title_fullStr | Postneoadjuvant therapy: a new approach to the treatment of HER2-positive breast cancer (KATHERINE study results) |
| title_full_unstemmed | Postneoadjuvant therapy: a new approach to the treatment of HER2-positive breast cancer (KATHERINE study results) |
| title_short | Postneoadjuvant therapy: a new approach to the treatment of HER2-positive breast cancer (KATHERINE study results) |
| title_sort | postneoadjuvant therapy a new approach to the treatment of her2 positive breast cancer katherine study results |
| topic | breast cancer her2-positive breast cancer adjuvant therapy trastuzumab emtansine t-dm1 katherine idfs residual tumor |
| url | https://www.med-sovet.pro/jour/article/view/5135 |
| work_keys_str_mv | AT lgzhukova postneoadjuvanttherapyanewapproachtothetreatmentofher2positivebreastcancerkatherinestudyresults AT sasmolin postneoadjuvanttherapyanewapproachtothetreatmentofher2positivebreastcancerkatherinestudyresults |